

DAFTAR PUSTAKA

Peraturan Perundang-Undangan

Peraturan Menteri Kesehatan Republik Indonesia Nomor 1799/MENKES/PER/XII/2010 Tentang Industri Farmasi.

Undang-Undang Nomor 5 Tahun 1999 Tentang Larangan Praktik Monopoli dan Persaingan Usaha Tidak Sehat.

Undang-Undang Nomor 13 Tahun 2016 Tentang Paten.

Putusan dan Pendapat Komisi

European Commission. Commission Decision of 19 June 2013 Relating to a Proceeding under Article 101 of the Treaty on the Functioning of the European Union and Article 53 of the EEA Agreement (Case AT.39226 — Lundbeck). Brussels: European Commission, 2013.

European Union General Court. Case T-472/13, Lundbeck v. Commission, Judgment of the General Court (Ninth Chamber), 8 September 2016.

Federal Trade Commission v. Actavis, Inc., 570 U.S. 136 (2013).

Buku

Dewata, Mukti Fajar Nur. *Dualisme Penelitian Hukum : Normatif & Empiris*. Yogyakarta: Pustaka Pelajar, 2010.

Hariyani, Iswi. *Prosedur Mengurus HAKI Yang Benar*. 1st ed. Yogyakarta: Pustaka Yustisia, 2008.

Kamus Besar Bahasa Indonesia.

Komisi Pengawas Persaingan Usaha. *Hukum Persaingan Usaha*. Komisi Pengawas Persaingan Usaha, 2017.

Kurnia, Titon Slamet. *Hak Atas Derajat Kesehatan Optimal Sebagai HAM Di Indonesia*. Alumni, 2007.

Marzuki, Peter Mahmud. *Penelitian Hukum*. Prenada Media, 2017.

Muhaimin. *Metode Penelitian Hukum*. Mataram: Mataram University Pers, 2020.

Sebastian, Pompe., et al. (Edit.). *Ikhtisar Ketentuan Hukum Persaingan Usaha*. Jakarta: The Indonesia Netherlands National Legal Reform, 2010, 272.

Siswanto, Arie. *Hukum Persaingan Usaha*. Ghalia Indonesia, 2002, 27.

Soekanto, Soerjono, and Sri Mamudji. *Penelitian Hukum Normatif : Suatu Tinjauan Singkat*. Jakarta: Rajawali, 1985.

Syafrinaldi, Fahmi, and Abdi Almaktsur. *Hak Kekayaan Intelektual*. Pekanbaru: Suska Press, 2002.

Surud, Margono. *Hukum Anti Monopoli*. Jakarta: Sinar Grafika, 2009, 103

Jurnal

Adachi, Kiyoshi. “The Emergence of ‘Pay-for-Delay’ Agreements in East Asia.” *Asian Journal of Law and Economics* 16, no. 3 (2025): 307–323. <https://doi.org/10.1515/ajle-2025-0006>

A. M. Tri Anggaraini. “Penerapan Pendekatan”Rule of Reason” dan “Per Se Illegal” dalam Hukum Persaingan, dalam Persaingan dan Persekongkolan Tender.” *Jurnal Hukum Bisnis* 24, No.2. (2005): 5.

Christianingrum, Ratna, dan Mujiburrahman. “Dinamika Industri Farmasi: Setengah Dekade Pasca Rencana Induk Pengembangan Industri Nasional Memaksimalkan Iklim Investasi Dari Perjanjian IK-CEPA.” *Buletin APBN VI*, no. 7 (2021). <https://berkas.dpr.go.id/pa3kn/buletin-apbn/public-file/buletin-apbn-public-123.pdf>.

Colomo, Ibáñez, Pablo, The Legal Status of Pay-for-Delay Agreements in EU Competition Law: Generics (Paroxetine) (September 16, 2020). Forthcoming in (2020) 57 *Common Market Law Review*, Available at SSRN: <https://ssrn.com/abstract=3693746> or <http://dx.doi.org/10.2139/ssrn.3693746>.

Debora. “Penerapan Pendekatan *Rule of Reason* terhadap Bentuk Kartel Berdasarkan Hukum Persaingan Usaha di Indonesia (Studi terhadap Putusan KPPU Nomor: 03/KPPU-I/2003, Putusan KPPU Nomor: 10/KPPU-L/2005 dan Putusan KPPU Nomor:11/KPPU-L/2005).” *Tesis, Program Pascasarjana Fakultas Hukum Universitas Indonesia* (Juli, 2008)

Dewi, Meryanti. “Praktek Monopoli dalam Industri Air Bersih di Pulau Batam di Tinjau dari Hukum Persaingan Usaha (Studi Kasus Perkara No. 11/KPPU-I/2008 Tentang Praktek Monopoli oleh PT. Adhy Tirta Batam).” *Tesis, Program Pascasarjana Fakultas Hukum Universitas Indonesia*. (2012): 52.

Feldman, Robin. “Antitrust Law: Pharmaceutical ‘Pay for Delay’ Reexamined.” *The Judges Book* 5, no. 1 (January 1, 2021): 4.

Gubby, Helen. “Is the Patent System a Barrier to Inclusive Prosperity? The Biomedical Perspective.” *Global Policy* 11, no. 1 (September 6, 2019). <https://doi.org/10.1111/1758-5899.12730>.

Jemart, W. “Pendekatan Rule of Reason Dan Per Se Illegal Dalam Perkara Persaingan Usaha.” *Widya Yuridika: Jurnal Hukum* 3, no 2. (2020):380

Lakeveld, Rivhard. “Chapter 16 - Control System Implementation and Plant-Wide Control of Continuous Pharmaceutical Manufacturing Pilot Plant (End-To-End Manufacturing Process).” In *Process Systems Engineering for Pharmaceutical Manufacturing*. Tsinghua University, Beijing, China: Elsevier, 2018.

Nash, David B. “Health Inequities in America.” *AM Health Drug Benefit* 10, no. 6 (January 2017): 279–80.

Rossi, Clifford V. “A Comparative Investment Analysis of Batch Versus Continuous Pharmaceutical Manufacturing Technologies.” *J Pharm Innov* 17, (2022): 1373-1291. <https://doi.org/10.1007/s12247-021-09612-y>

Internet

Alo Dokter. “45% Masyarakat Indonesia Masih Lebih Percaya Obat Herbal Dibanding Obat Modern.” www.alodokter.com, Februari 19, 2024. <https://www.alodokter.com/45-masyarakat-indonesia-masih-lebih-percaya-obat-herbal-dibanding-obat-modern>

Australia, Healthdirect. “Generic Medicines vs. Brand-Name Medicines.” www.healthdirect.gov.au, April 20, 2020. <https://www.healthdirect.gov.au/generic-medicines-vs-brand-name-medicines>.

Budiwati, Agnes Christina. “Direktorat Jenderal Pelayanan Kesehatan.” yankes.kemkes.go.id, n.d. https://yankes.kemkes.go.id/view_artikel/2434/obat-generik-dan-obat-paten.

Dailey, John W. “Pharmaceutical Industry.” In *Encyclopædia Britannica*, 2018. <https://www.britannica.com/technology/pharmaceutical-industry>.

DebateUS. “Problems with Drug Patents - DebateUS.” DebateUS, 2024. <https://debateus.org/problems-with-drug-patents/>.

Federal Trade Commission. “Pay for Delay.” Federal Trade Commission, October 31, 2018. <https://www.ftc.gov/news-events/topics/competition-enforcement/pay-delay>.

- Federal Trade Commission. “The Antitrust Laws.” Federal Trade Commission, n.d. <https://www.ftc.gov/advice-guidance/competition-guidance/guide-antitrust-laws/antitrust-laws>.
- Federal Trade Commission. “The Enforcers.” Federal Trade Commission, June 11, 2013. <https://www.ftc.gov/advice-guidance/competition-guidance/guide-antitrust-laws/enforcers>.
- GPFarmasi. “Industri Farmasi Optimistis Andil Ke Ekonomi Meningkat Di 2023 - GP Farmasi Indonesia - Gabungan Perusahaan Farmasi Indonesia.” GPFarmasi. Accessed October 14, 2024. <https://www.gpfarmasi.id/detailpost/industri-farmasi-optimistis-andil-ke-ekonomi-meningkat-di-2023>.
- Hilmas, Elora. “Understanding Medicines and What They Do (for Teens) - KidsHealth.” Kidshealth.org, October 2018. <https://kidshealth.org/en/teens/meds.html>.
- Kilick, James. “The ECJ’s Lundbeck Judgment Offers Little New on Patent Settlements but Gives Birth to an Interesting Principle: Sector Inquiries Give Rise to a Duty of Diligence | White & Case LLP.” www.whitecase.com, March 26, 2021. <https://www.whitecase.com/insight-alert/ecjs-lundbeck-judgment-offers-little-new-patent-settlements-gives-birth-interesting>.
- Mandal, Ananya. “Drug Patents and Generic Pharmaceutical Drugs.” News-Medical.net, February 27, 2019. <https://www.news-medical.net/health/Drug-Patents-and-Generics.aspx>.
- Mapara, Sandra. “Competition Law: Spotlight on the Pharmaceutical Sector.” Burges Salmon, April 17, 2020. <https://www.burges-salmon.com/news-and-insight/legal-updates/competition/competition-law-spotlight-on-the-pharmaceutical-sector>.
- Medical, Southeastern. “Medicines and How They Work.” Southeastern Medical Oncology Center, June 2, 2015. <https://www.cancersmoc.com/treatment/medicines-and-how-they-work/>.
- Mubarok, Fithrul. “Top 10 Perusahaan Farmasi Terbesar Indonesia Terbaru - FARMASI INDUSTRI.” Farmasi Industri, September 25, 2017. <https://farmasiindustri.com/industri/top-10-perusahaan-farmasi-indonesia.html>.
- Muhammad Teguh Maulana. “Monopoli Harga Obat Jadi Akar Masalah Defisit BPJS.” Indonesia for Global Justice, March 17, 2019.

<https://igj.or.id/2019/03/17/monopoli-harga-obat-jadi-akar-masalah-defisit-bpjs/>.

PhRMA. “What Is Hatch-Waxman?” phrma.org. Accessed October 14, 2024.
https://www.phrma.org/-/media/Project/PhRMA/PhRMA-Org/PhRMA-Org/PDF/D-F/Fact-Sheet_What-is-Hatch-Waxman_June-2018.pdf.

Sherlya Puspita Sari. “Obat Paten, Kenali Seluk-Beluknya.” Alodokter, July 25, 2023.
<https://www.alodokter.com/obat-paten-kenali-perbedaannya-dengan-obat-generik>.

United Nation Human Right. “OHCHR | Access to Medicines - a Fundamental Element of the Right to Health.” OHCHR, n.d.
<https://www.ohchr.org/en/development/access-medicines-fundamental-element-right-health>.

University Hospitals. “Generic vs. Brand-Name Drugs: Is There a Difference?”
www.uhhospitals.org, July 21, 2022.
<https://www.uhhospitals.org/blog/articles/2022/07/generic-vs-brand-name-drugs-is-there-a-difference>.

West, Zack. “Generics & Biosimilars: Novel New Therapies to Sidestep Drug Development Woes.” Crowd Funded Cures, March 29, 2022.
<https://crowdfundedcures.org/generics-and-biosimilars-market/>.

WIPO. “What Is Intellectual Property?” WIPO, 2016. <https://www.wipo.int/about-ip/en/>.